Patents Assigned to Mitsubishi Tanabe Pharma Corporation
  • Patent number: 11957660
    Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: April 16, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Tetsuo Hayama, Tomohiro Takahashi, Tomoyuki Omura, Kouji Hayashi, Munetomo Matsuda, Tadashi Miyazawa
  • Patent number: 11958812
    Abstract: Provided is a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of diseases involving ATX. A carboxylic acid compound represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: April 16, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Taichi Takahashi, Hisayuki Takamatsu, Daisuke Iijima, Shuzo Takeda
  • Publication number: 20240092762
    Abstract: The present invention provides: a methyl 1-{2-[(3S,4R) -1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4 -methoxyphenyl)pyrrolidine-3-carbonyl]-4 -(methoxymethyl)pyrrolidin-3-yl]-5 -(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof; and a production method using this compound.
    Type: Application
    Filed: October 31, 2023
    Publication date: March 21, 2024
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Joji TSURUMOTO, Kenji MOROKUMA
  • Publication number: 20240075011
    Abstract: A method for treating amyotrophic lateral sclerosis includes administering an effective amount of 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof to a patient who is in need thereof and meets two or more features selected from a group of identified features.
    Type: Application
    Filed: November 2, 2023
    Publication date: March 7, 2024
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Charlotte MERRILL, Wendy AGNESE, Nazem ATASSI, Tara GRABOWSKY, Takeshi SAKATA
  • Patent number: 11911366
    Abstract: A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: February 27, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Hidetoshi Shimizu, Yoshinobu Nakamaru, Yukiko Nishimura
  • Patent number: 11890288
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: July 20, 2023
    Date of Patent: February 6, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi Ohba, Yasuki Niwa, Tetsuji Matsudaira, Maiko Hamada, Ryuta Yamazaki, Tatsuya Ibuki
  • Publication number: 20240033248
    Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
    Type: Application
    Filed: September 29, 2023
    Publication date: February 1, 2024
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Tetsuo HAYAMA, Tomohiro TAKAHASHI, Tomoyuki OMURA, Kouji HAYASHI, Munetomo MATSUDA, Tadashi MIYAZAWA
  • Publication number: 20240009167
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Application
    Filed: September 21, 2023
    Publication date: January 11, 2024
    Applicants: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru MINAMINO
  • Patent number: 11845738
    Abstract: The present invention provides: a methyl 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof; and a production method using this compound.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: December 19, 2023
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Joji Tsurumoto, Kenji Morokuma
  • Patent number: 11826352
    Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: November 28, 2023
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Tetsuo Hayama, Tomohiro Takahashi, Tomoyuki Omura, Kouji Hayashi, Munetomo Matsuda, Tadashi Miyazawa
  • Publication number: 20230366867
    Abstract: A method of analyzing phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient includes obtaining a first measured value by measuring a phenylhydrazine content of a standard solution including phenylhydrazine or a salt thereof, a first acidic water and a first water-soluble organic solvent and having a phenylhydrazine concentration of 0.01 ?g/mL to 10 ?g/mL, obtaining a second measured value by measuring a phenylhydrazine content in a sample solution including a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, a second acidic water and a second water-soluble organic solvent, and detecting a phenylhydrazine content in a 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient based on the first measured value and second measured value.
    Type: Application
    Filed: July 27, 2023
    Publication date: November 16, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takeshi WAKASUGI, Aya SANO
  • Publication number: 20230365513
    Abstract: The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosilate, and the like.
    Type: Application
    Filed: September 15, 2021
    Publication date: November 16, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takafumi YAMAGAMI, Tomofumi SETSUTA, Yoshihiro SUGIURA, Naoko UEDA
  • Publication number: 20230364105
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: July 20, 2023
    Publication date: November 16, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyomi OHBA, Yasuki NIWA, Tetsuji MATSUDAIRA, Maiko HAMADA, Ryuta YAMAZAKI, Tatsuya IBUKI
  • Patent number: 11813244
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: November 14, 2023
    Assignees: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru Minamino
  • Patent number: 11802135
    Abstract: The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: October 31, 2023
    Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY
    Inventors: Maiko Hamada, Yuki Arai, Shuhei Yamakoshi, Hiroko Wada, Kazufumi Otsuki, Hiroaki Shitama, Nobuyuki Takakura
  • Publication number: 20230312542
    Abstract: The present invention provides a target protein degradation-inducing compound that is a bifunctional compound having a portion that binds to VHL, which is a substrate recognition protein of a ubiquitin ligase complex, at one end, and a portion that binds to a target protein at the other end. Specifically, a compound represented by the following structural formula (I): wherein each symbol is as defined in the present specification, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 5, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Shuhei YAMAKOSHI, Kouhei ISHIZAWA, Shuichi HAGIHARA, Komei SAKATA, Yasuki NIWA, Minoru TANAKA
  • Publication number: 20230285374
    Abstract: This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1), including methods suitable for conversion, correction, and maintenance therapy for patients. For example, methods described herein are durable, with efficacy observed for 24-52 weeks. Methods described herein can be particularly beneficial for patients converting from a previous anemia treatment comprising administration of an erythropoietin stimulating agent (ESA) such as darbepoetin alfa (DA), CKD patients on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels.
    Type: Application
    Filed: October 29, 2020
    Publication date: September 14, 2023
    Applicants: Akebia Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation
    Inventors: Emil deGoma, Nobuko Maruyama, Genki Kaneko
  • Patent number: 11746099
    Abstract: The present invention provides a process for preparing a compound represented by formula (VII), which comprises reacting a compound represented by formula (VI) with a malonic acid derivative in the presence of a base and an asymmetric catalyst in a two layer solvent system of hydrophobic solvent and water, (wherein R2 and R3 each independently represents a protecting group for carboxyl group).
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: September 5, 2023
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Takao Teshima, Takafumi Yamagami, Tetsuo Yamaguchi, Junki Ando
  • Publication number: 20230272386
    Abstract: A myoregulin inhibitor such as an antisense oligonucleotide against myoregulin or an anti-myoregulin antibody is used as an active ingredient of a prophylactic or therapeutic agent for a muscle disease such as muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, disused muscular atrophy, and sarcopenia.
    Type: Application
    Filed: July 16, 2021
    Publication date: August 31, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kiyoshi ISHIKAWA, Shumpei MURATA
  • Publication number: 20230270722
    Abstract: A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.
    Type: Application
    Filed: May 3, 2023
    Publication date: August 31, 2023
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Hidetoshi SHIMIZU, Yoshinobu NAKAMARU, Yukiko NISHIMURA